{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:26Z","timestamp":1783075886820,"version":"3.54.6"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/jcp.0b013e3182977308","type":"journal-article","created":{"date-parts":[[2013,6,15]],"date-time":"2013-06-15T11:05:57Z","timestamp":1371294357000},"page":"485-490","source":"Crossref","is-referenced-by-count":25,"title":["High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms"],"prefix":"10.1097","volume":"33","author":[{"given":"Donald C.","family":"Goff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold W.","family":"Mech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan R.","family":"Bustillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo C.","family":"Manschreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Achtyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Macklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2","key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2010.08040484","article-title":"Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).","volume":"168","author":"Strom","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3","key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14740338.2011.560114","article-title":"Drug safety evaluation of ziprasidone.","volume":"10","author":"Citrome","year":"2011","journal-title":"Expert Opin Safety"},{"issue":"12","key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics.","volume":"24","author":"Davis","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4088\/JCP.08m04531","article-title":"How dosing of ziprasidone in a state hospital system differs from product labeling.","volume":"70","author":"Citrome","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14740338.4.4.653","article-title":"Higher than Physicians Desk Reference (US) doses on atypical antipsychotics.","volume":"4","author":"Goodnick","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/BF02244926","article-title":"Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-1: a study using positron emission tomography and 11C-raclopride.","volume":"112","author":"Bench","year":"1993","journal-title":"Psychopharmacol"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.","volume":"18","author":"Goff","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mgday and 160 mgday in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial.","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacol"},{"issue":"2","key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mgday in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacol"},{"issue":"1-3","key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2009.03.009","article-title":"Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.","volume":"111","author":"Citrome","year":"2009","journal-title":"Schizophr Res"},{"issue":"5","key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D(2) and serotonin 5-HT(2) receptor occupancy in patients With schizophrenia treated with therapeutic doses of ziprasidone.","volume":"161","author":"Mamo","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"1","key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4088\/JCP.08m04104","article-title":"The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.","volume":"70","author":"Gandelman","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"R17-6-20210128","first-page":"58","article-title":"The effect of food on the absorption of oral ziprasidone.","volume":"40","author":"Miceli","year":"2007","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1592\/phco.30.2.127","article-title":"Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder.","volume":"30","author":"Miceli","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"3","key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clinthera.2010.03.003","article-title":"Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.","volume":"32","author":"Miceli","year":"2010","journal-title":"Clin Ther"},{"issue":"1","key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/j.1875-9114.1998.tb03820.x","article-title":"The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone.","volume":"18","author":"Hamelin","year":"1998","journal-title":"Pharmacotherapy"},{"issue":"11","key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/0091270010387604","article-title":"Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study.","volume":"51","author":"Wessels","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death.","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3182977308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T12:32:57Z","timestamp":1715517177000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201308000-00006"}},"subtitle":["The ZEBRAS Study"],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182977308","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}